Context Until recently, purchasers’ options regarding whether to pay for the use of technologies have been binary in nature: a treatment is covered or not covered. However, policies have emerged which expand the options - for example, linking coverage to evidence development, an option...

In DRG-based hospital payment systems, expensive drugs are often funded separately. In France, specific expensive drugs (including a large proportion of anticancer drugs) are fully reimbursed up to national reimbursement tariffs to ensure equity of access. Our objective was to analyse the use of...

LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment. </AbstractSection> Copyright Springer-Verlag 2013

This paper outlines a study and technology that teleports the knowledge and skills of doctors when and where they are needed resulting in a reduction of costs by reducing the number of patients who must be transported from remote areas to cities where specialists are located. Rapid access to...